abbvie glp-1 receptor agonist weight management diabetes treatments Agonists as for Type 2 Pharmacology Consult: GLP-1 receptor agonists

Common GLP-1 medications prescribed in 2025 include: Semaglutide (Wegovy, Ozempic) Tirzepatide (Mounjaro) Liraglutide (Saxenda) Peer-reviewed clinical trials published in journals such as The New England Journal of Medicine and JAMA document average body weight reductions of approximately 1022% over 612 months when GLP-1 medications are combined with lifestyle support and ongoing physician oversight

Diab Care 37 , 21492158 (2014)

Regular monitoring is important for people taking GLP-1 medication

This is expected and does not necessarily indicate a problem, but monitoring during the transition is important

Eye Lond Engl

Challenges in studies of GLP-1 and in development of GLP-1R agonists In the era of rapid daily progress in biomedical science, it is surprising that it took almost 20 years from identification of GLP-1 to successful approval of the worlds first clinically utilized GLP-1R agonist